Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 8;10(10):928–930. doi: 10.1016/S2213-2600(22)00222-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Illustration of two different therapeutic monoclonal antibodies (y-shaped) binding to different antigenic sites on a SARS-CoV-2 virus spike protein (red). SARS-CoV-2 causes the respiratory disease Covid-19. Antibodies are proteins of the immune system that bind to specific antigens, such as a viral protein, and either mark the pathogen for destruction by other immune cells, or destroy it themselves. Cocktails of antibodies have been shown to be effective against SARS-CoV-2 variants that are able to evade the immune response. — © 2022 Juan Gaertner/Science Photo Library